BAL 101553

Drug Profile

BAL 101553

Alternative Names: BAL-101553; BAL-27862

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Preclinical Brain cancer; Breast cancer

Most Recent Events

  • 02 Dec 2016 Phase-I/II clinical trials in Glioblastoma (Late-stage disease) in United Kingdom (PO)
  • 06 Sep 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Switzerland (IV)
  • 09 Jun 2016 Adverse events and efficacy data from a phase I/II trial in Solid tumours presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top